Patricia M. LoRusso, DO, on Targeting KRAS: Clinical Successes and Challenges

April 12, 2022 By The ASCO Post Staff

Patricia M. LoRusso, DO, of the Yale University School of Medicine, discusses how patients may benefit in the coming decade from discoveries about agents that target KRAS, and how important the approval of sotorasib turned out to be, as well as other agents in the research pipeline. Dr. LoRusso also talks about the scientific advances in tackling inhibition (Abstract SY20).

Related Content